Market Cap (In USD)
5.56 Billion
Revenue (In USD)
-
Net Income (In USD)
-126.21 Million
Avg. Volume
568.08 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 61.795-113.51
- PE
- -19.71
- EPS
- -3.93
- Beta Value
- 1.328
- ISIN
- US6707031075
- CUSIP
- 670703107
- CIK
- 1861560
- Shares
- 71797477.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. James R. Porter Ph.D.
- Employee Count
- -
- Website
- https://www.nuvalent.com
- Ipo Date
- 2021-07-29
- Details
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
More Stocks
-
UNH
-
2692
-
VBL
-
EFIREGPI Firecreek, Inc.
EFIR
-
6518
-
CLF
-
GZDIFGrizzly Discoveries Inc.
GZDIF
-
MCBI